Trident Texofab [TTFL] vs Trident [TRIDENT] Detailed Stock Comparison
Trident Texofab
BSE
Loading...
Trident
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Trident Texofab wins in 4 metrics, Trident wins in 15 metrics, with 0 ties. Trident appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Trident Texofab | Trident | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 158.94 | 33.66 | Trident |
| Price-to-Book Ratio | 7.32 | 3.30 | Trident |
| Debt-to-Equity Ratio | 62.67 | 35.39 | Trident |
| PEG Ratio | 36.56 | 0.42 | Trident |
| EV/EBITDA | 83.32 | 16.29 | Trident |
| Profit Margin (TTM) | 2.28% | 6.27% | Trident |
| Operating Margin (TTM) | 5.90% | 11.49% | Trident |
| EBITDA Margin (TTM) | 5.90% | 11.49% | Trident |
| Return on Equity | 5.31% | 8.00% | Trident |
| Return on Assets (TTM) | 2.50% | 5.17% | Trident |
| Free Cash Flow (TTM) | $-137.22M | $7.15B | Trident |
| Dividend Yield | N/A | 1.66% | N/A |
| 1-Year Return | 606.97% | -19.52% | Trident Texofab |
| Price-to-Sales Ratio (TTM) | 4.08 | 2.10 | Trident |
| Enterprise Value | $5.04B | $157.85B | Trident |
| EV/Revenue Ratio | 4.05 | 2.27 | Trident |
| Gross Profit Margin (TTM) | 15.72% | 51.29% | Trident |
| Revenue per Share (TTM) | $108 | $14 | Trident Texofab |
| Earnings per Share (Diluted) | $2.13 | $0.85 | Trident Texofab |
| Beta (Stock Volatility) | -1.25 | -0.05 | Trident Texofab |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Trident Texofab vs Trident Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Trident Texofab | 1.91% | 8.03% | 33.90% | 59.72% | 104.69% | 101.11% |
| Trident | -0.70% | 0.96% | 0.64% | -8.71% | 11.72% | -16.10% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Trident Texofab | 606.97% | 201.18% | 1,145.49% | 698.61% | 698.61% | 698.61% |
| Trident | -19.52% | -21.52% | 264.23% | 557.64% | 1,460.99% | 691.36% |
News Based Sentiment: Trident Texofab vs Trident
Trident Texofab
News based Sentiment: POSITIVE
September was a month of consistently positive developments for Trident Texofab, marked by strong stock performance, positive financial results, and overwhelmingly bullish investor sentiment. The company's continued outperformance and operational efficiency suggest a strong investment case, despite high valuation metrics.
Trident
News based Sentiment: MIXED
October was a month of strategic positioning for Trident Ltd. with the announcement of diversification into chemicals and paper. While quarterly revenue declined slightly, profitability and cash flow improved, creating a mixed but potentially positive outlook for investors. The stock's recent underperformance adds a layer of complexity.
Performance & Financial Health Analysis: Trident Texofab vs Trident
| Metric | TTFL | TRIDENT |
|---|---|---|
| Market Information | ||
| Market Cap | ₹5.08B | ₹148.42B |
| Market Cap Category | Small cap | Mid cap |
| 10 Day Avg. Volume | 24,786 | 3,843,252 |
| 90 Day Avg. Volume | 20,038 | 5,438,297 |
| Last Close | ₹345.00 | ₹28.41 |
| 52 Week Range | ₹146.25 - ₹345.00 | ₹23.11 - ₹40.20 |
| % from 52W High | 0.00% | -29.33% |
| All-Time High | ₹345.00 (Oct 06, 2025) | ₹70.35 (Jan 17, 2022) |
| % from All-Time High | 0.00% | -59.62% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.09% | -0.02% |
| Quarterly Earnings Growth | 0.46% | 0.90% |
| Financial Health | ||
| Profit Margin (TTM) | 0.02% | 0.06% |
| Operating Margin (TTM) | 0.06% | 0.11% |
| Return on Equity (TTM) | 0.05% | 0.08% |
| Debt to Equity (MRQ) | 62.67 | 35.39 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹46.27 | ₹8.67 |
| Cash per Share (MRQ) | ₹2.24 | ₹1.31 |
| Operating Cash Flow (TTM) | ₹-106,030,000 | ₹8.42B |
| Levered Free Cash Flow (TTM) | ₹25.10M | ₹3.70B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 1.66% |
| Last 12-Month Dividend | ₹0.00 | ₹0.50 |
Valuation & Enterprise Metrics Analysis: Trident Texofab vs Trident
| Metric | TTFL | TRIDENT |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 158.94 | 33.66 |
| Forward P/E | N/A | 23.84 |
| PEG Ratio | 36.56 | 0.42 |
| Price to Sales (TTM) | 4.08 | 2.10 |
| Price to Book (MRQ) | 7.32 | 3.30 |
| Market Capitalization | ||
| Market Capitalization | ₹5.08B | ₹148.42B |
| Enterprise Value | ₹5.04B | ₹157.85B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 4.05 | 2.27 |
| Enterprise to EBITDA | 83.32 | 16.29 |
| Risk & Other Metrics | ||
| Beta | -1.25 | -0.05 |
| Book Value per Share (MRQ) | ₹46.27 | ₹8.67 |
Financial Statements Comparison: Trident Texofab vs Trident
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | TTFL | TRIDENT |
|---|---|---|
| Revenue/Sales | ₹280.77M | ₹17.07B |
| Cost of Goods Sold | ₹236.63M | ₹8.31B |
| Gross Profit | ₹44.14M | ₹8.75B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹16.56M | ₹1.96B |
| EBITDA | ₹25.03M | ₹3.12B |
| Pre-Tax Income | ₹13.69M | ₹1.88B |
| Income Tax | ₹3.53M | ₹477.80M |
| Net Income (Profit) | ₹10.16M | ₹1.40B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | TTFL | TRIDENT |
|---|---|---|
| Cash & Equivalents | ₹1.09M | ₹663.40M |
| Total Current Assets | ₹737.44M | ₹25.10B |
| Total Current Liabilities | ₹407.50M | ₹12.50B |
| Long-Term Debt | ₹102.71M | ₹10.15B |
| Total Shareholders Equity | ₹472.39M | ₹46.21B |
| Retained Earnings | ₹77.13M | ₹26.84B |
| Property, Plant & Equipment | ₹31.11M | ₹99.20M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | TTFL | TRIDENT |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | TTFL | TRIDENT |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 24,786 | 3,843,252 |
| Average Daily Volume (90 Day) | 20,038 | 5,438,297 |
| Shares Outstanding | 13.56M | 5.08B |
| Float Shares | 7.61M | 1.20B |
| % Held by Insiders | 0.38% | 0.76% |
| % Held by Institutions | 0.00% | 0.02% |
Dividend Analysis & Yield Comparison: Trident Texofab vs Trident
| Metric | TTFL | TRIDENT |
|---|---|---|
| Last 12-Month Dividend | ₹0.00 | ₹0.50 |
| Last 12-Month Dividend Yield | N/A | 1.66% |
| 3-Year Avg Annual Dividend | ₹0.00 | ₹0.53 |
| 3-Year Avg Dividend Yield | N/A | 1.15% |
| 3-Year Total Dividends | ₹0.00 | ₹1.58 |
| Ex-Dividend Date | N/A | May 27, 2025 |